Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Dose Amelubant in Cystic Fibrosis
NCT02265679Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2001
- Primary completion
- Jul 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of amelubant in cystic fibrosis (CF) (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Changes from baseline in physical examination up to 5 days, Number of patients with clinically relevant changes in vital signs up to 5 days and 5 more. Started Oct 2001; status: completed.
02
Drugs
amelubant
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02265679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265679.